Tag: New England Journal of Medicine

Genentech’s HEMLIBRA® Offers Promise to Hemophilia Patients

South San Francisco, CA   August 30, 2018 Press Release Positive Phase III Results for Genentech’s HEMLIBRA® (emicizumab-kxwh) for Hemophilia A Without Factor VIII Inhibitors Published in New England Journal of Medicine — HEMLIBRA prophylaxis significantly reduced bleeds compared to no…